Treatment of inflamed pterygia or residual pterygial bed.
OBJECTIVE
To describe the use of subconjunctival bevacizumab or ranibizumab, an approved antivascular endothelial growth factor for wet macular degeneration, in halting the inflammation of a pterygium or a partially excised pterygium.


METHODS
Case reports.


RESULTS
Prompt regression of conjunctival microvessels in the pterygial bed was documented 1 week after a single subconjunctival injection of ranibizumab (one case) or bevacizumab (two cases). No side-effects were noted over 13 months of follow-up in the first case, 6 months in the second case and 1 month in the third case.


CONCLUSIONS
Selective blockade of vascular endothelial growth factor was effective in causing regression of conjunctival microvessels in three eyes with inflamed pterygium or residual pterygia.
Mansour
A M
AM
Department of Ophthalmology, American University of Beirut, PO Box 113-6044, Beirut, Lebanon. dr.ahmad@cyberia.net.lb
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva / Q000098:blood supply; D016510:Corneal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D055806:Microvessels / Q000187:drug effects; D008875:Middle Aged; D018918:Phacoemulsification; D011625:Pterygium / Q000188:drug therapy*; D000069579:Ranibizumab; D014821:Vitrectomy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab